| Ms Nora Gant, ARNP, MN | |
|
4525 3rd Ave Se Ste 200, Lacey, WA 98503-1010 | |
| (360) 493-4504 | |
| (360) 412-8922 |
| Full Name | Ms Nora Gant |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 18 Years |
| Location | 4525 3rd Ave Se Ste 200, Lacey, Washington |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306064472 | NPI | - | NPPES |
| 9652421 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LA2200X | Nurse Practitioner - Adult Health | AP30007610 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Centralia Hospital | Centralia, WA | Hospital |
| Providence St Peter Hospital | Olympia, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Providence Health And Services Washington | 6709782600 | 393 |
News Archive
Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference therapeutics, announced today it has initiated patient dosing in a Phase 1 human clinical trial for its lead oncology product, TKM-PLK1. TKM-PLK1 targets polo-like kinase 1, or PLK1, a cell cycle protein involved in tumor cell proliferation and a validated oncology target.
Critically ill patients in hospital intensive care units (ICUs) are routinely prescribed acid-suppressive medications to reduce their risk of developing stress ulcers and gastrointestinal bleeding, both of which can result from being in a stressful environment and from being intubated. Over the years, this routine practice has often been extended to patients outside the ICU, despite a lack of evidence that this population is at significant risk of these complications.
Many children who require insulin treatment on diagnosis with Type 2 diabetes can be weaned off the medication, show findings from the run-in phase of the Treatment Options for Type 2 Diabetes in Adolescents and Youth study.
Among patients with castration-resistant prostate cancer, the addition of hormone therapy following vaccine treatment improved overall survival compared with either treatment alone or when the vaccine followed hormone treatment, according to recent data published in the July 15 Clinical Cancer Research, a journal of the American Association for Cancer Research.
If the idea of keeping a food and exercise diary keeps you from joining a weight-loss program, there may be a better way.
› Verified 8 days ago
| Entity Name | Providence Health & Services Washington |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174744304 PECOS PAC ID: 6709782600 Enrollment ID: O20031211000028 |
News Archive
Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference therapeutics, announced today it has initiated patient dosing in a Phase 1 human clinical trial for its lead oncology product, TKM-PLK1. TKM-PLK1 targets polo-like kinase 1, or PLK1, a cell cycle protein involved in tumor cell proliferation and a validated oncology target.
Critically ill patients in hospital intensive care units (ICUs) are routinely prescribed acid-suppressive medications to reduce their risk of developing stress ulcers and gastrointestinal bleeding, both of which can result from being in a stressful environment and from being intubated. Over the years, this routine practice has often been extended to patients outside the ICU, despite a lack of evidence that this population is at significant risk of these complications.
Many children who require insulin treatment on diagnosis with Type 2 diabetes can be weaned off the medication, show findings from the run-in phase of the Treatment Options for Type 2 Diabetes in Adolescents and Youth study.
Among patients with castration-resistant prostate cancer, the addition of hormone therapy following vaccine treatment improved overall survival compared with either treatment alone or when the vaccine followed hormone treatment, according to recent data published in the July 15 Clinical Cancer Research, a journal of the American Association for Cancer Research.
If the idea of keeping a food and exercise diary keeps you from joining a weight-loss program, there may be a better way.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Nora Gant, ARNP, MN 4525 3rd Ave Se Ste 200, Lacey, WA 98503-1010 Ph: (360) 493-4504 | Ms Nora Gant, ARNP, MN 4525 3rd Ave Se Ste 200, Lacey, WA 98503-1010 Ph: (360) 493-4504 |
News Archive
Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference therapeutics, announced today it has initiated patient dosing in a Phase 1 human clinical trial for its lead oncology product, TKM-PLK1. TKM-PLK1 targets polo-like kinase 1, or PLK1, a cell cycle protein involved in tumor cell proliferation and a validated oncology target.
Critically ill patients in hospital intensive care units (ICUs) are routinely prescribed acid-suppressive medications to reduce their risk of developing stress ulcers and gastrointestinal bleeding, both of which can result from being in a stressful environment and from being intubated. Over the years, this routine practice has often been extended to patients outside the ICU, despite a lack of evidence that this population is at significant risk of these complications.
Many children who require insulin treatment on diagnosis with Type 2 diabetes can be weaned off the medication, show findings from the run-in phase of the Treatment Options for Type 2 Diabetes in Adolescents and Youth study.
Among patients with castration-resistant prostate cancer, the addition of hormone therapy following vaccine treatment improved overall survival compared with either treatment alone or when the vaccine followed hormone treatment, according to recent data published in the July 15 Clinical Cancer Research, a journal of the American Association for Cancer Research.
If the idea of keeping a food and exercise diary keeps you from joining a weight-loss program, there may be a better way.
› Verified 8 days ago
Cynthia A Ramsey, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1350 Marvin Rd Ne Ste D, Lacey, WA 98516 Phone: 888-227-3312 Fax: 360-413-6509 | |
Sheree Harvey, DNP, ARNP, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 669 Woodland Square Loop Se, Lacey, WA 98503 Phone: 360-359-4840 | |
Jodi Fischer, ARNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1450 Northwest Ln Se Ste A, Lacey, WA 98503 Phone: 360-491-4460 Fax: 360-491-3090 | |
Carrie Welty, ARNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2555 Marvin Rd Ne, Pmg Sw Wa Hawks Prairie Fm, Lacey, WA 98516 Phone: 360-413-4200 | |
Consilia Samkia Yeluma, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 606 Woodland Square Loop Se, Lacey, WA 98503 Phone: 360-359-8951 | |
Mr. Prachanda Khadka, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2555 Marvin Rd Ne, Lacey, WA 98516 Phone: 360-413-4200 Fax: 360-413-4225 | |
Meghan Neal, ARNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1350 Marvin Rd Ne Ste D, Lacey, WA 98516 Phone: 888-227-3312 |